SBIR/STTR Research Award

Novel Approaches to Accessing Secondary Metabolites

Award identifier 2eeed62e690af9284e2efe0fd6de66f5fe91368dfe585e54c4c68afcad0e1335Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$999,578

Program and phase

SBIR · Phase I

Award year

2005

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
NOVOBIOTIC PHARMACEUTICALS, LLC
Proposal award date
Not reported
Contract end date
Not reported
UEI
GUV4CZLZE5Z2
Solicitation number
PHS2005-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): The overall goal of this project is to develop novel therapeutic agents against Yersinia pestis, the causative agent of plague and one of the most dangerous potential bioweapons. In this exploratory project, we will develop novel approaches to obtain previously inaccessible secondary metabolites from actinomycetes. These organisms have traditionally served as the main source for antibiotics. Recent whole genome sequencing of two well-studied streptomycete species revealed potential additional modules for synthesis of antibiotics. This agrees well with previous data from the literature indicating that the majority of antibiotics are not expressed under in vitro growth conditions. It is reasonable to assume that antibiotics are expressed in a natural environment, where they provide a competitive advantage to the producing organism. Our overall approach is to emulate the natural environment to elicit production of antibiotics. We will develop two elicitation methods in this project. According to our preliminary data, there is a particular type of compounds that emulate a critical aspect of the environment and act as antibiotic elicitors. A detailed examination of the ability of these substances to elicit production of previously unknown antibiotics will be performed with a panel of known actinomycetes. Another method of antibiotic elicitation will be based on culturing microorganisms in their natural environment, soil, in a diffusion chamber that we have previously used to grow "unculturable" microorganisms (Kaeberlein, T., Lewis, K., and Epstein, S.S. (2002) Science 296:1127-1129). Finding new compounds with antimicrobial activity from known organisms using elicitation will constitute proof of principle for the proposed approach. The methods we develop will allow for large-scale screening and validation in Phase II which will lead to the development of a new anti-Y. pestis therapy.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

25 SBIR/STTR records share this UEI (2004–2023). Reported award amounts total $36,654,092. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services, National Science Foundation

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.